stockrow
Friday 6 November 2026
Export PRAX’s income statement to Excel — free account
Praxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
276.75
14.16
+5.39%
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Total debt
Praxis Precision Medicines, Inc.'s total debt at the end of fiscal 2022 was $3.5M, down 18.8% from $4.3M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $2.8M. Praxis Precision Medicines, Inc. ranks 326th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $3.5M | (18.81%) |
| FY2021 | $4.3M | 465.01% |
| FY2020 | $763.0K | (47.70%) |
| FY2019 | $1.5M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $2.8M | (8.44%) |
| Jun 2023 | $3.0M | (7.67%) |
| Mar 2023 | $3.3M | (6.86%) |
| Dec 2022 | $3.5M | (6.24%) |
| 9 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $864.1M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| AXSM Axsome Therapeutics, Inc. compare | $127.3M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | $106.1M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| CORT Corcept Therapeutics Incorporated compare | $5.0M |
| PRAX Praxis Precision Medicines, Inc. | $2.8M |
| ABVX Abivax SA Sponsored ADR compare | $1.4M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt